<i>A20</i> SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients

Zhu, Lihua; Zhou, Lingling; Wang, Liang; Li, Zhaoxia; Lü, Shuai; Lijian, Yang; Chen, Shaohua; Li, Bo; Wu, Xiuli; Zhou, Yi; Li, Yangqiu

doi:10.1111/ajco.12577

Cited by 9 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, four of them (rs5029937, rs598493, rs2230926 and rs582757) were also identified in the SS sample, the significance may be the case with rs2230926 TG genotype and rs5029937 GT genotype, which were identified in rare RA cases with poor clinical outcome. More importantly, we also found that rs77191406 was identified in few cases with SLE and RA, and an RA patient who was heterozygous for rs77191406 developed colon cancer 10 years after the RA diagnosis, similarly, one rs77191406 heterozygous SLE patient underwent bladder cancer 5 years after SLE diagnosis . Because, chronic inflammation was a common feature in skin lesion of SS case.…”

Section: Resultssupporting

confidence: 57%

Different genetic alteration of A20 in a Sézary syndrome case with Vα2‐Jα22 T cell clone

Zhou

Zheng

Huang

et al. 2017

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 57%

Different genetic alteration of A20 in a Sézary syndrome case with Vα2‐Jα22 T cell clone

Zhou

Zheng

Huang

et al. 2017

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…24 Some studies showed that TNFAIP3 could play an important role in immune and inflammatory responses mediated by cytokines. [24][25][26]…”

Section: Tnfaip3 Basic Characteristics Of Tnfaip3mentioning

confidence: 99%

<p>Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects</p>

Guo¹,

Yuan²

2020

OTT

View full text Add to dashboard Cite

Tumor necrosis factor (TNF) is the first cytokine used in tumor biotherapy, but TNFrelated drugs are limited by the lack of specific targets. Tumor necrosis factor alpha-induced proteins (TNFAIPs), derived from TNF, is a protein family and participates in proliferation, invasion and metastasis of tumor cells. In order to better understand biological functions and potential roles of TNFAIPs in malignant tumors, this paper in the form of "Gene-Protein-Tumor correlation" summarizes the biological characteristics, physiological functions and mechanisms of TNFAIPs by searching National Center of Biotechnology Information, GeneCards, UniProt and STRING databases. The relationship between TNFAIPs and malignant tumors is analyzed, and protein-protein interaction diagram in members of TNFAIPs is drawn based on TNF for the first time. We find that TNF as a key factor is related to TNFAIP1, TNFAIP3, TNFAIP5, TNFAIP6, TNFAIP8 and TNFAIP9, which can be directly involved in activating TNFAIP1, TNFAIP5, TNFAIP8 and TNFAIP9. We confirm that the mechanism of TNFAIP1, TNFAIP2 and TNFAIP3 inducing tumors may be related to NF-κB signaling pathway, but the mechanism of tumor induction by other members of TNFAIPs is not clear. In the future, translational studies are needed to explore the mechanisms of TNF-TNFAIPs-tumors.

show abstract

“…Okada et al found that polymorphisms of TNFAIP3 were common to both rheumatoid arthritis and Hodgkin’s lymphoma [104]. In the only study examining TNFAIP3 in SLE, Zhu and Zhou [105] reported that two of 37 patients with SLE were heterozygous for an A20 gene polymorphism ( rs77191406 ); one developed bladder cancer with liver metastases while the other had severe SLE, including central nervous system and renal involvement. Hence, rs77191406 may be an important prognostic marker for malignancy risk and SLE severity.…”

Section: Factors Potentially Mediating Riskmentioning

confidence: 99%

A review on SLE and malignancy

Choi

Flood

Bernatsky

et al. 2017

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. It predominantly affects young and middle-aged women. While improvements in the diagnosis and treatment of SLE have altered prognosis, morbidity and mortality rates remain higher than the general population. In addition to renal injury, cardiovascular disease, and infection, malignancy is known to be a significant cause of death in this population. There is increasing evidence to suggest that patients with SLE have a slightly higher overall risk of malignancy. The risk of malignancy in SLE is of considerable interest because the immune and genetic pathways underlying the pathogenesis of SLE and the immunosuppressant drugs (ISDs) used in its management may mediate this altered risk. Our current understanding of these and other risk factors and the implications for treating SLE and screening for malignancy is still evolving. This review summarizes the association between SLE and malignancy. The first section discusses the risk of overall and site-specific malignancies in both adult- and pediatric-onset SLE. Next, we evaluate the risk factors and possible mechanisms underlying the link between malignancy and SLE, including the use of ISDs, presence of certain SLE-related autoantibodies, chronic immune dysregulation, environmental factors, and shared genetic susceptibility. Finally, we review guidelines regarding cancer screening and vaccination for human papilloma virus.

show abstract

A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients

Abstract: These findings suggest that rs77191406 may be a prognostic marker for a high risk for rapid malignancy progression, poor survival and refractory disease and a new molecular marker associated with autoimmune diseases transforming into a secondary cancer.

Cited by 9 publications

References 23 publications

Different genetic alteration of A20 in a Sézary syndrome case with Vα2‐Jα22 T cell clone

Different genetic alteration of A20 in a Sézary syndrome case with Vα2‐Jα22 T cell clone

<p>Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects</p>

A review on SLE and malignancy

Contact Info

Product

Resources

About